As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Although GLP-1 agonists have many advantages, they can have disadvantages. Notably, the gastrointestinal (GI) system is frequently affected by GLP1 side effects. Furthermore, minor skin responses at ...

Positive comments regarding their experiences have been provided by customers: “When it comes to my GLP1 side effects, these drops have been invaluable. In a matter of minutes, they soothe my tummy.” ...

One of the key uncertainties facing 89bio is the potential impact of GLP-1 therapies and other obesity ... dosing and lower gastrointestinal side effects, could improve patient compliance and ...

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.